Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis.

Publication Type
Journal Article
Year of Publication
Whitcup, S M; Fortin, E; Lindblad, A S; Griffiths, P; Metcalf, J A; Robinson, M R; Manischewitz, J; Baird, B; Perry, C; Kidd, I M; Vrabec, T; Davey, R T; Falloon, J; Walker, R E; Kovacs, J A; Lane, H C; Nussenblatt, R B; Smith, J; Masur, H; Polis, M A
Date Published
1999 Nov 03
Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Cytomegalovirus; Cytomegalovirus Retinitis; Disease Progression; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Viral Load

CONTEXT: Persons with cytomegalovirus (CMV) retinitis and acquired immunodeficiency syndrome (AIDS) have required lifelong anti-CMV therapy to prevent the progression of retinal disease and subsequent loss of vision.

OBJECTIVE: To determine whether patients who were taking highly active antiretroviral therapy (HAART) and who had stable CMV retinitis could safely discontinue anti-CMV therapy without reactivation of their retinitis or increase in human immunodeficiency virus (HIV) viral load.

DESIGN: Prospective nonrandomized interventional trial performed from July 1997 to August 1999.

SETTING: Clinical Center of the National Institutes of Health, Bethesda, Md.

PATIENTS: Fourteen patients with stable CMV retinitis and HIV infection and CD4+ cell counts higher than 0.1 5 x 10(9)/L and being treated with systemic anti-CMV medications and HAART.

INTERVENTIONS: Discontinuation of specific anti-CMV therapy.

MAIN OUTCOME MEASURES: Reactivation of CMV retinitis, development of extraocular CMV infection, detection of CMV in blood and urine, HIV burden, immunologic function, quality of life, morbidity, and mortality.

RESULTS: Twelve (89.7%) of 14 patients had evidence of immune recovery uveitis before anti-CMV drugs were discontinued. No patient had reactivation of CMV retinitis or development of extraocular CMV disease during mean follow-up of 16.4 months (range, 8.3-22.0 months) without anti-CMV therapy. Human immunodeficiency viral load remained stable following cessation of anti-CMV medications. Blood and urine assays for CMV were briefly positive in 9 patients but did not predict reactivation of CMV disease. Worsening immune recovery uveitis was associated with a substantial (>3 lines) vision loss in 3 patients.

CONCLUSIONS: Maintenance anti-CMV medications were safely stopped in those patients who had stable CMV retinitis and elevated CD4+ cell counts and who were taking HAART. The study demonstrates that immune recovery following potent antiretroviral therapy is effective in controlling a major opportunistic infection, even in patients with a history of severe immunosuppression.